A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma
The survival rate needs to be improved in early stage non-small cell lung cancer patients. The risk of recurrence is relatively high in invasive adenocarcinoma patients with a solid or micropapillary component, lymphovascular invasion or tumor spread through air spaces. Systemic treatment options including radical surgical resection should be explored for this population. Adjuvant chemotherapy is not recommended for patients in stage IA in current guidelines. This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with pathological high-risk factors in stage IA lung adenocarcinoma..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Chinese Journal of Lung Cancer - 25(2022), 8, Seite 593-600 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Chen SHEN [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adjuvant chemotherapy |
|---|
| doi: |
10.3779/j.issn.1009-3419.2022.101.30 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ030461529 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ030461529 | ||
| 003 | DE-627 | ||
| 005 | 20230501173207.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2022 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3779/j.issn.1009-3419.2022.101.30 |2 doi | |
| 035 | |a (DE-627)DOAJ030461529 | ||
| 035 | |a (DE-599)DOAJ54ff93e402aa4ee8bb686cd900e508b6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 050 | 0 | |a RC254-282 | |
| 100 | 0 | |a Chen SHEN |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The survival rate needs to be improved in early stage non-small cell lung cancer patients. The risk of recurrence is relatively high in invasive adenocarcinoma patients with a solid or micropapillary component, lymphovascular invasion or tumor spread through air spaces. Systemic treatment options including radical surgical resection should be explored for this population. Adjuvant chemotherapy is not recommended for patients in stage IA in current guidelines. This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with pathological high-risk factors in stage IA lung adenocarcinoma. | ||
| 650 | 4 | |a lung neoplasms | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a adjuvant chemotherapy | |
| 653 | 0 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| 700 | 0 | |a Wentao FANG |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Chinese Journal of Lung Cancer |d Chinese Anti-Cancer Association; Chinese Antituberculosis Association, 2008 |g 25(2022), 8, Seite 593-600 |w (DE-627)DOAJ000017493 |x 19996187 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:8 |g pages:593-600 |
| 856 | 4 | 0 | |u https://doi.org/10.3779/j.issn.1009-3419.2022.101.30 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/54ff93e402aa4ee8bb686cd900e508b6 |z kostenfrei |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.30 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1009-3419 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1999-6187 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 8 |h 593-600 | ||